Ulrik Pedersen-Bjergaard Selected Research

Long-Acting Insulin (Insulin, Long Acting)

1/2022	Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.
11/2021	Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update.
7/2019	The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
6/2012	A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ulrik Pedersen-Bjergaard Research Topics

Disease

50	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2022 - 03/2008
28	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 04/2003
14	Type 2 Diabetes Mellitus (MODY) 02/2022 - 11/2006
4	Diabetes Mellitus 01/2022 - 05/2018
4	Hyperglycemia 07/2021 - 06/2018
3	Nausea 01/2020 - 01/2008
3	Cognitive Dysfunction 01/2013 - 03/2008
2	COVID-19 01/2022 - 11/2020
2	Cardiac Arrhythmias (Arrythmia) 12/2021 - 07/2021
2	Ischemia 01/2020 - 02/2017
2	Spinal Cord Compression 06/2018 - 05/2018
2	Neoplasms (Cancer) 06/2018 - 10/2014
2	Vomiting 03/2016 - 01/2008
2	Inappropriate ADH Syndrome (SIADH) 10/2014 - 12/2012
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2021
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 07/2021
1	Hypersensitivity (Allergy) 11/2020
1	Infections 11/2020
1	Glucose Intolerance 11/2020
1	Fever (Fevers) 08/2020
1	Edema (Dropsy) 08/2018
1	Brain Neoplasms (Brain Tumor) 08/2018
1	Reperfusion Injury 02/2017
1	ST Elevation Myocardial Infarction 02/2017
1	Coronary Occlusion 02/2017
1	Overweight 03/2016
1	Dyspepsia (Indigestion) 03/2016
1	Weight Loss (Weight Reduction) 03/2016
1	Gestational Weight Gain 12/2015
1	Diabetic Nephropathies (Diabetic Nephropathy) 06/2015
1	Infarction (Infarctions) 01/2015
1	Myocardial Infarction 01/2015
1	Osteoporosis 10/2014
1	Olfactory Esthesioneuroblastoma (Esthesioneuroblastoma) 10/2014
1	Pre-Eclampsia (Preeclampsia) 09/2011

Drug/Important Bio-Agent (IBA)

34	Insulin (Novolin)FDA Link 02/2022 - 03/2005
30	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 01/2008
10	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 04/2003
7	Blood Glucose (Blood Sugar)IBA 02/2022 - 12/2013
5	insulin degludecIBA 01/2022 - 07/2019
5	Insulin Glargine (Lantus)FDA Link 01/2022 - 07/2019
5	GlucocorticoidsIBA 06/2020 - 05/2018
5	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 06/2015 - 03/2008
4	Long-Acting Insulin (Insulin, Long Acting)FDA Link 01/2022 - 06/2012
3	Insulin Detemir (Levemir)FDA Link 11/2021 - 07/2014
3	C-PeptideIBA 01/2018 - 06/2009
2	Isophane Insulin (NPH Insulin)FDA Link 11/2021 - 06/2020
2	CarbohydratesIBA 01/2020 - 06/2018
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2020 - 03/2016
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2020 - 02/2017
2	Hemoglobins (Hemoglobin)IBA 01/2018 - 11/2010
2	Glucagon (Glukagon)FDA Link 10/2017 - 11/2016
2	Liraglutide FDA Link 02/2017 - 03/2016
2	Glucagon-Like Peptide 1 (GLP 1)IBA 02/2017 - 03/2016
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 12/2015 - 11/2009
2	Vasopressins (Vasopressin)IBA 10/2014 - 12/2012
2	Erythropoietin FDA Link 01/2013 - 07/2009
1	insulin receptor-related receptor (IRR)IBA 12/2021
1	Pioglitazone (Actos)FDA Link 11/2020
1	Oxygen (Dioxygen)IBA 08/2020
1	Exenatide (Byetta)FDA Link 01/2020
1	Protamines (Protamine Sulfate)FDA Link 01/2018
1	Insulin Aspart (NovoLog)FDA Link 10/2016
1	Saline SolutionIBA 03/2016
1	Insulin-Like Growth Factor I (IGF-1)IBA 12/2015
1	candesartanIBA 12/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2015
1	Angiotensin Receptor AntagonistsIBA 12/2015
1	Growth Hormone (Somatotropin)IBA 12/2015
1	Hydrocortisone (Cortisol)FDA LinkGeneric 05/2015
1	Epinephrine (Adrenaline)FDA LinkGeneric 05/2015
1	Troponin T (Troponin T1)IBA 01/2015
1	SodiumIBA 10/2014
1	Hormones (Hormone)IBA 01/2013
1	Brain Natriuretic Peptide (Natrecor)FDA Link 09/2011
1	Atrial Natriuretic Factor (ANF)IBA 09/2011
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2009
1	AngiotensinogenIBA 03/2008
1	Psychotropic Drugs (Psychoactive Drugs)IBA 03/2005

Therapy/Procedure

13	Therapeutics 01/2022 - 11/2006
3	Injections 01/2022 - 01/2020
2	Glycemic Control 01/2022 - 07/2012
2	Subcutaneous Injections 01/2020 - 03/2016
1	Polypharmacy 01/2020
1	Transjugular Intrahepatic Portasystemic Shunt 06/2018
1	Radiotherapy 05/2018
1	Ischemic Postconditioning 02/2017
1	Emergency Treatment 11/2009